Targeting cathepsins: A potential link between COVID-19 and associated neurological manifestations.
Heliyon
; 7(10): e08089, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1440044
ABSTRACT
Many studies have shown that the lysosomal cathepsins, especially cathepsins B/L (CTSB/L) are required for SARS-CoV-2 entry into host cells. Lysosomal proteases, cathepsins are indispensable for normal health and are involved in several brain disorders occurring at different development age periods. On the other hand, it has been well known that COVID-19 infection is largely associated with several neurological disorders. Taken together these findings and given the high levels of expression of CTSB/L in the brain, we here proposed a reasonable hypothesis about the involvement of CTSB/L in the neurological manifestations linked to COVID-19. Pharmacological inhibitions of the CTSB/L could be a potential therapeutic target to block the virus entry as well as to mitigate the brain disorders. To this end, we utilized the network-based drug repurposing analyses to identify the possible drugs that can target CTSB/L. This study identifies the molecules like cyclosporine, phenytoin, and paclitaxel as potential drugs with binding ability to the CTSB/L. Further, we have performed molecular docking and all-atom molecular dynamics (MD) simulations to investigate the stability of CTSL-drug complexes. The results showed strong and stable binding of drugs with CTSL.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Journal:
Heliyon
Year:
2021
Document Type:
Article
Affiliation country:
J.heliyon.2021.e08089
Similar
MEDLINE
...
LILACS
LIS